

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)

The following resolutions were passed at the Annual General Meeting (the "AGM") of Asarina Pharma AB (publ) (the "Company") on 27 June 2024 at Fredersen Advokatbyrå's premises at Birger Jarlsgatan 8, Stockholm.

Adoption of income statement and balance sheet and discharge from liability

The AGM resolved to adopt the income statement for the financial year 2023 as well as the balance sheet and consolidated balance sheet as of 31 December 2023. The members of the Board of Directors and the Managing Director were discharged from liability for the financial year 2023.

Allocation of profit or loss

The AGM resolved, in accordance with the Board of Directors' proposal, that no dividend shall be paid for 2023 and that the results of the company shall be carried forward.

Board of Directors and auditor

The AGM resolved, in accordance with the nomination committee's proposal, on re-election of Paul de Potocki, Erin Gainer and Marianne Kock as board members. Paul de Potocki was re-elected as the Chairman of the Board of Directors. The AGM re-elected the audit firm Ernst & Young Aktiebolag as auditor.

The AGM further resolved on remuneration to the Board of Directors in accordance with the Nomination Committee's proposal. The Board members proposed for re-election declared their willingness to waive their respective remuneration until the Company has received financing and/or entered into partnerships that enable payment thereof. The AGM furthermore resolved in accordance with the Nomination Committee's proposal, that remuneration to the auditor shall be paid in accordance with approved statement of costs.

Nomination Committee for the next Annual General Meeting

The AGM resolved, in accordance with the Nomination Committee's proposal, that the principles for the appointment of the Nomination Committee adopted at the AGM 2020 shall continue to apply also for the appointment of the Nomination Committee ahead of the AGM 2025.

For further information, please contact:

Peter Nordkild, CEO, Asarina Pharma AB

Phone: +45 25 47 16 46


E-mail: peter.nordkild@asarinapharma.com

Jakob Dynnes Hansen, CFO, Asarina Pharma AB

Tel: +45 5132 3698

E-mail: jakob.dynnes@asarinapharma.com

The Company's Certified Adviser is Carnegie Investment Bank AB (publ)





About Asarina Pharma

Asarina Pharma is a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments.

Attachments

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)